Voices
Ezra Cohen: Targeted Therapies for RET-Driven Lung Cancer Deliver Dramatic Curative Outcomes
Ezra Cohen/LinkedIn

Ezra Cohen: Targeted Therapies for RET-Driven Lung Cancer Deliver Dramatic Curative Outcomes

Ezra Cohen, Chief Medical Officer of Oncology at Tempus Labs, shared a post on LinkedIn:

“The paradigm extends to RET. Treating lung cancer patients in the curative setting with targeted therapies when their tumors harbor driver alterations, improves outcomes dramatically.”

Title: Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

Authors: Yi-Long Wu, Maximilian Hochmair, Yi Yang, Xue-Ning Yang, Masahiro Tsuboi, Luis Paz-Ares, James Chih-Hsin Yang, Lin Wu, Hye Ryun Kim, Damian Rieke, Melissa Johnson, Benjamin Besse, Nivedita Sharma, Patricia Maeda, Patrick Peterson, Boris Kin Lin, Bente Frimodt-Moller, Jonathan Goldman, Alexander Drilon

Read the Full Article.

Ezra Cohen: Targeted Therapies for RET-Driven Lung Cancer Deliver Dramatic Curative Outcomes

Other articles about Lung Cancer on OncoDaily.

Alexander Drilon Benjamin Besse Bente Frimodt-Moller Boris Kin Lin cancer Damian Rieke Ezra Cohen Hye Ryun Kim James Chih-Hsin Yang Jonathan Goldman Lin Wu Luis Paz-Ares Lung cancer Masahiro Tsuboi Maximilian Hochmair Melissa Johnson Nivedita Sharma OncoDaily Oncology Patricia Maeda Patrick Peterson Xue-Ning Yang Yi Yang Yi-Long Wu